Topic

Vice President, Neuroscience, Scientific Solutions at Worldwide Clinical Trials

Articles

Renewed interest in psychedelic research shows great promise for patients in need of more effective therapies.

Why and How to Infuse Methodological Rigor into Psychedelic Clinical Trials

Kenneth Koblan, PhD, chief scientific officer at Sunovion, discusses novel therapy development and clinical trial challenges in mental health.

The Resurgence of New Mental Illness Treatments

Nabil Chehab, medical affairs head of lung cancer franchise at AstraZeneca, discuss strategies used in the Phase III AEGEAN trial for treating non-small lung cancer (NSCLC).

Using Solid Endpoint Strategies for Successful Cancer Trials

Richard Williams, PhD, chief medical officer at Kinnate Biopharma Inc. discusses clinical trial strategies and challenges.

Treating Oncogenic Mutations in Clinical Trials

Global Director, Biorepository Operations and Strategy, Avantor

Pursuing new tools and capabilities in sample logistics, storage, and data analysis.

Managing Biospecimens in Cell and Gene Therapy Trials

Project Manager in Clinical Operations, TRiNDS

Approaches sponsors, CROs, and investigators can take from the DMD experience.

Rare Disease Clinical Trials: Strategies Learned from Duchenne Muscular Dystrophy

As activity in this space grows, so do the hurdles in moving these products forward.

The Risk-Reward Proposition for CGT Clinical Trials

Director, eCOA Solutions Engineering, IQVIA

Industry now leveraging reporting system to empower patients and improve research.

   ePROs in Oncology: Breaking Through Barriers for Better Drug Development and Higher Quality Care

Sirj Goswami, PhD, CEO, co-founder of InsightRX

Vice president of Global Biopharma Strategy

Understanding Project Optimus

Pandemic has brought new sense of awareness to respiratory diseases and clinops.

Therapeutic Areas